temozolomide has been researched along with sb 225002 in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Acker, G; Brandenburg, S; Jelgersma, C; Koch, A; Kremenetskaia, I; Mueller, S; Nieminen-Kelhä, M; Rubarth, K; Urbantat, RM; Vajkoczy, P; Zollfrank, J | 1 |
1 other study(ies) available for temozolomide and sb 225002
| Article | Year |
|---|---|
Tumor-Associated Microglia/Macrophages as a Predictor for Survival in Glioblastoma and Temozolomide-Induced Changes in CXCR2 Signaling with New Resistance Overcoming Strategy by Combination Therapy.
Topics: Adult; Aged; Aged, 80 and over; Animals; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Disease Models, Animal; Drug Synergism; Female; Gene Expression Regulation, Neoplastic; Glioblastoma; Humans; Interleukin-8; Male; Mice; Middle Aged; Neoplasm Recurrence, Local; Neovascularization, Pathologic; Phenylurea Compounds; Prognosis; Receptors, Interleukin-8B; Signal Transduction; Survival Analysis; Temozolomide; Tumor Microenvironment; Tumor-Associated Macrophages; Young Adult | 2021 |